Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, 330000, China.
Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, No.1, Minde Road, Nanchang, 330000, China.
Dig Dis Sci. 2022 Jul;67(7):2994-3005. doi: 10.1007/s10620-021-07121-z. Epub 2021 Jul 8.
BACKGROUND: The current study set out to elucidate the specific role of microRNA (miR)-206 in cholangiocarcinoma (CCA) cell biological activities by negatively modulating jumonji AT-rich interactive domain 2 (JARID2). METHODS: Firstly, human intrahepatic biliary epithelial cells and CCA cell lines were selected via the analysis of miR-206 and JARID2 expression patterns in CCA by qRT-PCR. Next, the target relation between miR-206 and JARID2 was predicted by Targetscan and validated using dual-luciferase reporter gene assay and RNA immunoprecipitation (RIP) assay. Subsequently, CCK-8 method, colony formation assay, scratch test, Transwell assay, and western blot analysis were performed to evaluate cancer cell development after the overexpression of miR-206 and/or JARID2, with levels of invasion-related proteins assessed. In addition, xenograft transplantation was also employed to confirm the role of miR-206 in vivo. Lastly, Ki-67 expression pattern was also quantified with immunohistochemistry. RESULTS: It was found that miR-206 was poorly expressed and JARID2 was highly expressed in CCA cell lines. Also, miR-206 overexpression brought about a suppressive effect on cancer cell proliferation, migration, and invasion. Furthermore, miR-206 was observed to target JARID2. Meanwhile, JARID2 overexpression promoted cell growth, while simultaneous overexpression of miR-206 and JARID2 impeded malignant cancer progression, indicating that miR-206 overexpression inhibited cell progression via targeting JARID2. Finally, in vivo experimentation illustrated that miR-206 overexpression suppressed tumor growth and weight, and inhibited the expressions of JARID2 N-cadherin, vimentin, and Ki-67. CONCLUSION: Altogether, our findings clarified that miR-206 inhibited CCA malignancy by negatively regulating JARID2.
背景:本研究旨在通过负调控 jumonji AT 富含相互作用域 2(JARID2)来阐明 microRNA(miR)-206 在胆管癌(CCA)细胞生物学活性中的具体作用。
方法:首先,通过 qRT-PCR 分析 CCA 中 miR-206 和 JARID2 的表达模式,选择人肝内胆管上皮细胞和 CCA 细胞系。接下来,通过 Targetscan 预测 miR-206 和 JARID2 之间的靶关系,并通过双荧光素酶报告基因检测和 RNA 免疫沉淀(RIP)实验验证。随后,通过 CCK-8 法、集落形成实验、划痕实验、Transwell 实验和 Western blot 分析评估过表达 miR-206 和/或 JARID2 后癌细胞的发育情况,并评估侵袭相关蛋白的水平。此外,还进行了异种移植实验以在体内确认 miR-206 的作用。最后,通过免疫组化定量 Ki-67 的表达模式。
结果:研究发现,miR-206 在 CCA 细胞系中表达水平较低,而 JARID2 表达水平较高。此外,过表达 miR-206 可抑制癌细胞增殖、迁移和侵袭。进一步研究表明,miR-206 可靶向 JARID2。同时,过表达 JARID2 促进细胞生长,而过表达 miR-206 和 JARID2 则阻碍恶性肿瘤的进展,表明 miR-206 通过靶向 JARID2 抑制细胞进展。最后,体内实验表明,过表达 miR-206 可抑制肿瘤生长和重量,并抑制 JARID2、N-钙黏蛋白、波形蛋白和 Ki-67 的表达。
结论:总之,本研究结果表明,miR-206 通过负调控 JARID2 抑制 CCA 恶性肿瘤的发生。
J Cancer Res Clin Oncol. 2016-5
J Gastrointest Surg. 2022-4
Eur Rev Med Pharmacol Sci. 2020-8
Int J Clin Exp Pathol. 2018-7-1
Int J Clin Exp Pathol. 2018-7-1